Pancreaticoduodenectomy for locally advanced colon cancer in hereditary nonpolyposis colorectal cancer
Tóm tắt
Hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch syndrome, accounts for 3 % of newly diagnosed cases of colorectal cancer. While a partial or subtotal colectomy is indicated for early stage disease, there is a paucity of data addressing locally advanced disease involving the foregut. We report two patients with hereditary nonpolyposis colorectal cancer presenting with locally advanced colon cancer surgically managed by pancreaticoduodenectomy with en bloc partial colectomy and a review of the literature. Locally advanced colorectal cancer in HNPCC is a rare clinical entity that requires special surgical consideration. Multidisciplinary treatment, including multi-visceral resection, offers the best long-term outcome.
Tài liệu tham khảo
American Cancer Society. Cancer facts and figure 2014. Atlanta: American Cancer Society; 2014.
National Comprehensive Cancer Network. NCCN Guidelines Genetic/Familial High-Risk Assessment: Colorectal Version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed 30 Oct 2015.
Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A, Working Group of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med. 2014;16:101–16.
Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17:405–15.
You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum. 2008;51:1036–43.
Smith KD, Rodriguez-Bigas MA. Role of surgery in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome). Surg Oncol Clin N Am. 2009;18:705–15.
Temple SJ, Kim PT, Serrano PE, Kagedan D, Cleary SP, Moulton CA, et al. Combined pancreaticoduodenectomy and colon resection for locally advanced peri-ampullary tumours: analysis of peri-operative morbidity and mortality. HPB (Oxford). 2014;16:797–800.
Zhang J, Leng JH, Qian HG, Qiu H, Wu JH, Liu BN, et al. En bloc pancreaticoduodenectomy and right colectomy in the treatment of locally advanced colon cancer. Dis Colon Rectum. 2013;56:874–80.
Cirocchi R, Partelli S, Castellani E, Renzi C, Parisi A, Noya G, et al. Right hemicolectomy plus pancreaticoduodenectomy vs partial duodenectomy in treatment of locally advanced right colon cancer invading pancreas and/or only duodenum. Surg Oncol. 2014;23:92–8.
Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg. 2010;252:507–11. discussion 511-3.
Berg M, Guriby M, Nordgard O, Nedrebo BS, Ahlquist TC, Smaaland R, et al. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. Mol Med. 2013;19:286–93.
Samdani T, Schultheis M, Stadler Z, Shia J, Fancher T, Misholy J, et al. Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor? Dis Colon Rectum. 2015;58:288–93.
Sugimoto K, Sakamoto K, Tomiki Y, Goto M, Kotake K, Sugihara K. Proposal of new classification for stage III colon cancer based on the lymph node ratio: analysis of 4,172 patients from multi-institutional database in Japan. Ann Surg Oncol. 2015;22:528–34.
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15:1245–53.
de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer. 2004;109:468–71.